Susan D. Wyrick - 02 Jan 2026 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role: Acting Chief Financial Officer and Principal Accounting Officer
Signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick
Issuer symbol: SANA
Transactions as of: 02 Jan 2026
Net transactions value: -$10,278
Form type: 4
Filing time: 06 Jan 2026, 16:18:40 UTC
Previous filing: 16 Dec 2025
Next filing: 04 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wyrick Susan D.	Acting Chief Financial Officer and Principal Accounting Officer	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE	/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick	06 Jan 2026	0001568605

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SANA	Common Stock	Options Exercise	$0	+7,500	+4.1%	$0.000000	188,290	02 Jan 2026	Direct
transaction	SANA	Common Stock	Tax liability	$10,278	-2,407	-1.3%	$4.27	185,883	05 Jan 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SANA	Restricted Stock Units	Options Exercise		-7,500	-100%		0	02 Jan 2026	Common Stock	7,500		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.
F2	The award vested as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026.

Remarks:

Acting Chief Financial Officer and Principal Accounting Officer